Elinzanetant was approved last October for moderate to severe hot flashes and night sweats due to menopause, joining fezolinetant, which arrived in 2023. Both are hormone-free. Both came out of the same piece of basic neuroscience rather than out of hormone chemistry, and in the OASIS trials elinzanetant reduced the frequency and severity of vasomotor symptoms with improvements visible as early as the first week and sustained across 52 weeks.

For women who cannot take estrogen, or who have decided not to, this is the first time the alternative has been a drug designed for the problem rather than a repurposed antidepressant or blood pressure medication.

From the Lab to the Ledger

The mechanism is worth understanding because it explains both what these drugs do and what they do not.

Body temperature is regulated by a small cluster of neurons in the hypothalamus. Estrogen normally restrains them. As estrogen falls during menopause, those neurons enlarge and become overactive, and they signal using a neuropeptide called neurokinin B acting on the NK3 receptor. The result is a narrowed thermoneutral zone: a small rise in core temperature that would previously have passed unnoticed now triggers the full heat-dissipation response, which is what a hot flash is. Blocking the NK3 receptor calms those neurons directly, without replacing the hormone anywhere else in the body.

The clue came from an unexpected place. Researchers studying men with a rare genetic condition affecting neurokinin signalling noticed their flushing patterns, and the connection to menopausal hot flashes was made from there. It took roughly two decades to move from that observation to an approved drug, which is a fair illustration of the real timeline in this field.

Elinzanetant differs from fezolinetant in blocking both NK1 and NK3 receptors. The NK1 pathway is involved in sleep and mood regulation, and the trials reported improvements in sleep disturbance alongside the reduction in flashes. Whether that dual action is meaningfully better in practice has not been tested head to head.

The safety picture is where these two diverge in the practical sense. Fezolinetant carries a requirement for liver blood test monitoring, with baseline testing and checks over the first months, following reports of liver injury after approval. In the elinzanetant programme no liver toxicity cases were observed and the common adverse effects reported were headache, fatigue, dizziness and sleepiness. Post-approval surveillance covers far more people than any trial, so this is a picture that can still change, and it is the specific thing to ask a prescriber about.

Bio-Pipeline Ledger

Elinzanetant: approved last October for moderate to severe menopausal vasomotor symptoms, dual NK1 and NK3 receptor antagonist, with 52-week data behind it.

Fezolinetant: approved in 2023, NK3 only, effective, and requiring scheduled liver blood test monitoring after post-marketing reports of liver injury.

Systemic hormone therapy: still the most effective treatment for vasomotor symptoms, with its own risk profile that depends on timing, formulation and personal history. These drugs are an alternative, not a replacement.

Vaginal estrogen for genitourinary symptoms: a separate problem with a separate treatment, minimally absorbed, and not addressed by either of these drugs.

Older off-label options, including certain SSRIs and SNRIs, gabapentin and clonidine: modestly effective, inexpensive, familiar to prescribers, and still reasonable choices.

Supplements marketed for hot flashes, including black cohosh and soy isoflavones: trial results are inconsistent and mostly small, with placebo response in this symptom running unusually high, which is why the marketing is so persuasive.

Cognitive behavioural therapy for menopausal symptoms: evidence-supported for how much the symptoms interfere with life, even where the flash count changes little. Underused.

The Clinical Reality Check

What is established is that blocking neurokinin signalling in the hypothalamus reduces hot flashes and night sweats meaningfully, without hormones, and that two drugs now do it with trial evidence behind them. That is a genuine addition for women with a history of breast cancer, clotting disorders, or any other reason estrogen is off the table.

What is overstated is the framing of these as a general upgrade over hormone therapy. They treat vasomotor symptoms. They do not address bone loss, genitourinary symptoms, or anything else estrogen affects, and the comparative long-term safety data that hormone therapy has accumulated over decades does not yet exist for either of them. Cost is also a real factor, since both are new and branded.

The practical version is that the conversation with a clinician now has more than two outcomes. If hormone therapy was ruled out and nothing else worked, that is worth revisiting. If you are already taking fezolinetant, the liver monitoring schedule is not optional and is worth confirming you are on. And if hot flashes are disrupting sleep rather than the day, say that specifically, because the sleep effect is where these drugs and the alternatives differ most.